Syros Pharmaceuticals, Inc. Common Stock
SYRS Real Time Price USDRecent trades of SYRS by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by SYRS's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Inhibitors of cyclin dependent kinase 7 (cdk7) Mar. 05, 2024
-
Patent Title: Compounds for the modulation of myc activity Sep. 12, 2023
-
Patent Title: Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists Sep. 20, 2022
-
Patent Title: Inhibitors of cyclin dependent kinase 7 (cdk7) Apr. 26, 2022
-
Patent Title: Compounds for the modulation of myc activity Mar. 15, 2022
-
Patent Title: Compounds for the modulation of myc activity Sep. 21, 2021
-
Patent Title: Compositions of cyclin dependent kinase 7 (cdk7) inhibitor Aug. 10, 2021
-
Patent Title: Methods of stratifying patients for treatment with retinoic acid receptor-α agonists Jul. 06, 2021
-
Patent Title: Pyrrolotriazine compounds and methods of inhibiting tam kinases Jun. 22, 2021
-
Patent Title: Inhibitors of cyclin-dependent kinase 7 (cdk7) Dec. 15, 2020
-
Patent Title: Compounds for the modulation of myc activity Sep. 29, 2020
-
Patent Title: Inhibitors of cyclin-dependent kinase 7 (cdk7) Aug. 11, 2020
-
Patent Title: Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists Jun. 30, 2020
-
Patent Title: Inhibitors of cyclin-dependent kinase 7 (cdk7) Dec. 31, 2019
-
Patent Title: Inhibitors of cyclin-dependent kinase 7 (cdk7) Jul. 02, 2019
-
Patent Title: Inhibitors of cyclin-dependent kinase 7 (cdk7) Jun. 04, 2019
-
Patent Title: Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists Mar. 26, 2019
-
Patent Title: Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists Jan. 01, 2019
-
Patent Title: Inhibitors of cyclin-dependent kinase 7 (cdk7) Oct. 23, 2018
-
Patent Title: Inhibitors of cyclin-dependent kinase 7 (cdk7) Aug. 28, 2018
-
Patent Title: Methods of stratifying patients for treatment with retinoic acid receptor-α agonists Jan. 16, 2018
-
Patent Title: Methods of stratifying patients for treatment with retinoic acid receptor-alpha agonists Dec. 19, 2017
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of SYRS in WallStreetBets Daily Discussion
Recent insights relating to SYRS
Recent picks made for SYRS stock on CNBC
ETFs with the largest estimated holdings in SYRS
|
Shareholder
|
Shares Held
|
|---|
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view SYRS Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.